Page 2005 - Williams Hematology ( PDFDrive )

1980 Part XII: Hemostasis and Thrombosis Chapter 115: Vascular Function In Hemostasis 1981

17. Muller WA: Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol 54. Voetsch B, Loscalzo J: Genetic determinants of arterial thrombosis. Arterioscler Thromb
6:323–344, 2011. Vasc Biol 24:216–229, 2004.
18. Marcus AJ, Safier LB: Thromboregulation: Multicellular modulation of platelet reactiv- 55. Robson SC, Sevigny J, Zimmermann H: The E-NTPDase family of ectonucleotidases:
ity in hemostasis and thrombosis. FASEB J 7:516–522, 1993. Structure function relationships and pathophysiological significance. Purinergic Signal
19. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 340:115–126, 1999. 2:409–430, 2006.
20. Garlanda C, Dejana E: Heterogeneity of endothelial cells: Specific markers. Arterioscler 56. Gayle RB, Maliszewski CR, Gimpel SD, et al: Inhibition of platelet function by recom-
Thromb Vasc Biol 17:1193–1202, 1999. binant soluble ecto-ADPase/CD39. J Clin Invest 101:1851–1859, 1998.
21. Gawaz M, Langer H, May AE: Platelets in inflammation and atherogenesis. J Clin Invest 57. Handa M, Guidotti G: Purification and cloning of a soluble ATP-diphosphohydrolase
115:3378–3384, 2005. (apyrase) from potato tubers (Solanum tuberosum). Biochem Biophys Res Commun
22. May AE, Langer H, Seizer P, et al: Platelet-leukocyte interactions in inflammation and 218:916–923, 1996.
atherothrombosis. Semin Thromb Hemost 33:123–127, 2007. 58. Hyman MC, Ptrovic-Djergovic D, Visovatti SH, et al: Self-regulation of inflammatory cell
23. Brass LF, Zhu L, Stalker TJ: Novel therapeutic targets at the platelet vascular interface. trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest 119:1136–1149, 2009.
Arterioscler Thromb Vasc Biol 28(3):s43–s50, 2008. 59. Colgan S, Eltzschig H, Eckle T, Thompson L: Physiological roles for ecto-5′-nucleo-
24. Marcus AJ: Transcellular metabolism of eicosanoids. Prog Hemost Thromb 8:127–142, tidase (CD73). Purinergic Signal 2:351–360, 2006.
1986. 60. Atkinson BT, Jarvis GE, Watson SP: Activation of GPVI by collagen is regulated by
25. Hamberg M, Svensson J, Samuelsson B: Thromboxanes: A new group of biologically alpha2beta1 and secondary mediators. J Thromb Haemost 1:1278–1287, 2003.
active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 61. Pinsky DJ, Broekman MJ, Peschon JJ, et al: Elucidation of the thromboregulatory role of
72:2994–2998, 1975. CD39/ectoapyrase in the ischemic brain. J Clin Invest 109:1031–1040, 2002.
26. Moncada S, Gryglewski R, Bunting S, Vane JR: An enzyme isolated from arteries 62. Marcus AJ, Broekman MJ, Drosopoulos JHF, et al: Metabolic control of excessive extra-
transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet cellular nucleotide accumulation by CD39/ectonucleotidase-1: Implications for ische-
aggregation. Nature 263:663–665, 1976. mic vascular diseases. J Pharmacol Exp Ther 305:9–16, 2003.
27. Woulfe D, Yang J, Brass L: ADP and platelets: The end of the beginning. J Clin Invest 63. Koziak K, Bojakowska M, Robson SC, et al: Overexpression of CD39/nucleoside tri-
107:1503–1505, 2001. phosphate diphosphohydrolase-1 decreases smooth muscle cell proliferation and pre-
28. Al-Mondhiry H, Marcus AJ, Spaet TH: On the mechanism of platelet function inhibi- vents neointima formation after angioplasty. J Thromb Haemost 6:1191–1197, 2008.
tion by acetylsalicylic acid. Proc Soc Exp Biol Med 133:632–636, 1970. 64. Deaglio S, Dwyer KM, Gao W, et al: Adenosine generation catalyzed by CD39 and
29. Wu KK, Aird WC: Endothelial eicosanoids, in Endothelial Biomedicine, pp 1004–1014. CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med
Cambridge University Press, Cambridge, 2009. 204:1257–1265, 2007.
30. McAdam BF, Catella-Lawson F, Mardini IA, et al: Systemic biosynthesis of prostacyclin 65. Uluckan O, Eagleton MC, Floyd DH, et al: APT102, a novel ADPase, cooperates with
by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX- aspirin to disrupt bone metastasis in mice. J Cell Biochem 104:1311–1323, 2008.
2. Proc Natl Acad Sci U S A 96:272–277, 1999. 66. Dwyer KM, Robson SC, Nandurkar HH, et al: Thromboregulatory manifestations in
31. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1299:125–140, 1996. human CD39 transgenic mice and the implications for thrombotic disease and trans-
32. Maclouf J, Folco G, Patrono C: Eicosanoids and iso-eicosanoids: Constitutive, inducible plantation. J Clin Invest 113:1440–1446, 2004.
and transcellular biosynthesis in vascular disease. Thromb Haemost 79:691–705, 1998. 67. Serebruany VL, Malinin AI, Ferguson JJ, et al: Bleeding risks of combination vs. sin-
33. Smith WL, DeWitt DL: Prostaglandin endoperoxide H synthases-1 and -2. Adv Immu- gle antiplatelet therapy: A meta-analysis of 18 randomized trials comprising 129,314
nol 62:167–215, 1996. patients. Fundam Clin Pharmacol 22:315–321, 2008.
34. Xie WL, Chipman JG, Robertson DL, et al: Expression of a mitogen-responsive gene 68. Fung CY, Marcus AJ, Broekman MJ, Mahaut-Smith MP: P2X1 receptor inhibition and
encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U soluble CD39 administration as novel approaches to widen the cardiovascular thera-
S A 88:2692–2696, 1991. peutic window. Trends Cardiovasc Med 19:1–5, 2009.
35. Kurumbail RG, Stevens Am, Gierse JK, et al: Structural basis for selective inhibition of 69. Esmon CT, Owen WG: Identification of an endothelial cell cofactor for thrombin-cata-
cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644–648, 1996 [published lyzed activation of protein C. Proc Natl Acad Sci U S A 78:2249–2252, 1981.
erratum appears in Nature 385(6616):555, 1997]. 70. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, et al: The endothelial cell protein C
36. Pouliot M, Gilbert C, Borgeat P, et al: Expression and activity of prostaglandin endoper- receptor augments protein C activation by the thrombin-thrombomodulin complex.
oxide synthase-2 in agonist-activated human neutrophils. FASEB J 12:1109–1123, 1998. Proc Natl Acad Sci U S A 93:10212–10216, 1996.
37. DeWitt DL, Smith WL: Cloning of sheep and mouse prostaglandin endoperoxide syn- 71. Esmon CT: Protein C pathway in sepsis. Ann Med 34:598–605, 2002.
thases. Methods Enzymol 187:469–479, 1990. 72. Esmon CT: Inflammation and thrombosis. J Thromb Haemost 1:1343–1348, 2003.
38. Dubois RN, Abramson SB, Crofford L, et al: Cyclooxygenase in biology and disease. 73. Esmon CT: The protein C pathway. Chest 124(3 Suppl):26S–32S, 2003.
FASEB J 12:1063–1073, 1998. 74. Esmon CT: The roles of protein C and thrombomodulin in the regulation of blood
39. Lipsky LPE, Abramson SB, Crofford L, et al: The classification of cyclooxygenase inhib- coagulation. J Biol Chem 264:4743–4746, 1989.
itors. J Rheumatol 25:2298–2303, 1998. 75. Grinnell BW, Berg DT: Surface thrombomodulin modulates thrombin receptor
40. Marnett LJ: The COXIB experience: A look in the rear-view mirror. Annu Rev Pharma- responses on vascular smooth muscle cells. Am J Physiol 270:H603–H609, 1996.
col Toxicol 49:265–290, 2008. 76. Lafay M, Laguna R, Le Bonniec BF, et al: Thrombomodulin modulates the mitogenic
41. Moncada S, Vane JR: Pharmacology and endogenous roles of prostaglandin endoperox- response to thrombin of human umbilical vein endothelial cells. Thromb Haemost
ides, thromboxane A2, and prostacyclin. Pharmacol Rev 30:293–331, 1978. 79:848–852, 1998.
42. Narumiya S, FitzGerald GA: Genetic and pharmacologic analysis prostanoid receptor 77. Bajzar L, Manuel R, Nesheim M: Purification and characterization of TAFI, a thrombin
function. J Clin Invest 108:25–30, 2001. activatable fibrinolysis inhibitor. J Biol Chem 270:14477–14484, 1995.
43. Cines DB, Pollak ES, Buck CA, et al: Endothelial cells in physiology and in the patho- 78. Campbell WD, Okada N, Okada H: Carboxypeptidase R is an inactivator of comple-
physiology of vascular disorders. Blood 91:3527–3561, 1998. ment-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev
44. Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ: Synthesis of prostacyclin from plate- 180:162–167, 2001.
let-derived endoperoxides by cultured human endothelial cells. J Clin Invest 66:979– 79. Ikeguchi H, Fujita Y, Kato T, et al: Effects of human soluble thrombomodulin on exper-
986, 1980. imental glomerulonephritis. Kidney Int 61:490–501, 2002.
45. Smyth SS, McEver RP, Weyrich AS, et al: Platelet functions beyond hemostasis. J 80. de Munk GA, Groeneveld E, Rijken DC: Acceleration of the thrombin inactivation of
Thromb Haemost 7:1759–1766, 2009. single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomod-
46. Pepine CJ: Impact of nitric oxide on cardiovascular medicine: Untapped potential util- ulin. J Clin Invest 88:1680–1684, 1991.
ity. Am J Med 122:S10–S15, 2009. 81. Molinari A, Giogetti C, Lansen J, et al: Thrombomodulin is a cofactor for thrombin
47. Marletta MA: Nitric oxide synthase structure and mechanism. J Biol Chem 268:12231– degradation of recombinant single-chain urokinase plasminogen activator in vitro and
12234, 1993. in a perfused rabbit heart model. Thromb Haemost 67:226–232, 1992.
48. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology, and 82. Preissner KT, May AE, Wohn KD, et al: Molecular crosstalk between adhesion recep-
pharmacology. Pharmacol Rev 43:109–142, 1991. tors and proteolytic cascades in vascular remodeling. Thromb Haemost 78:88–95, 1997.
49. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of 83. Esmon CT, Scriver CR, Beaudet AL, et al: Anticoagulant protein C/thrombomodulin
arterial smooth muscle by acetylcholine. Nature 288:373–376, 1980. pathway, in The Metabolic and Molecular Bases of Inherited Disease, 8th ed, edited by
50. Matsumoto A, Momomura S, Sugiura S, et al: Effect of inhaled nitric oxide on gas Scriver CR, Beaudet AL, Valle D, Sly WS, Childs B, Kinzler KW, and Vogelstein B,
exchange in patients with congestive heart failure. Ann Intern Med 130:40–44, 1999. pp 4327–4343. McGraw-Hill New York, 2001.
51. Lentz SR, Sobey CG, Piegers DJ, et al: Vascular dysfunction in monkeys with diet- 84. Healy AM, Hancock WW, Christie PD, et al: Intravascular coagulation activation in a
induced hyperhomocyst(e)inemia. J Clin Invest 98:24–29, 1996. murine model of thrombomodulin deficiency: Effects of lesion size, age, and hypoxia
52. Stamler JS, Osborne JA, Jaraki O, et al: Adverse vascular effects of homocysteine are on fibrin deposition. Blood 263:15815–15822, 1988.
modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J 85. Weiler-Guettler H, Aird WC, Rayburn H, et al: Developmentally regulated gene expression of
Clin Invest 91:308–318, 1993. thrombomodulin in postimplantation mouse embryos. Development 122:2271–2281, 1996.
53. Upchurch GR Jr, Welch GN, Fabian AJ, et al: Homocyst(e)ine decrease bioavailable 86. Crawley JT, Gu AM, Ferrell G, Esmon CT: Distribution of endothelial cell protein C/
nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 272: activated protein C receptor (EPCR) during mouse embryo development. Thromb Hae-
17012–17017, 1997. most 88:259–266, 2002.

Kaushansky_chapter 115_p1967-1984.indd 1980 9/18/15 10:09 AM